Hyperleptinemia in children with autosomal recessive spinal muscular atrophy type I-III

被引:21
|
作者
Koelbel, Heike [1 ]
Hauffa, Berthold P. [2 ]
Wudy, Stefan A. [3 ]
Bouikidis, Anastasios [4 ]
Della Marina, Adela [1 ]
Schara, Ulrike [1 ]
机构
[1] Univ Duisburg Essen, Childrens Hosp 1, Dept Neuropediat Dev Neurol & Social Pediat, Essen, Germany
[2] Univ Duisburg Essen, Childrens Hosp 2, Dept Pediat Endocrinol, Essen, Germany
[3] Justus Liebig Univ, Ctr Child & Adolescent Med, Div Pediat Endocrinol & Diabetol, Steroid Res & Mass Spectrometry Unit, Giessen, Germany
[4] Univ Duisburg Essen, Childrens Hosp 3, Dept Pediat Pulmonol, Essen, Germany
来源
PLOS ONE | 2017年 / 12卷 / 03期
关键词
POLYCYSTIC-OVARY-SYNDROME; PUBERTAL CHANGES; MOUSE MODEL; LEPTIN; DISEASE; METABOLISM; GROWTH; RESISTANCE; SURVIVAL; INFANTS;
D O I
10.1371/journal.pone.0173144
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background Autosomal-recessive proximal spinal muscular atrophies (SMA) are disorders characterized by a ubiquitous deficiency of the survival of motor neuron protein that leads to a multisystemic disorder, which mostly affects alpha motor neurons. Disease progression is clinically associated with failure to thrive or weight loss, mainly caused by chewing and swallowing difficulties. Although pancreatic involvement has been described in animal models, systematic endocrinological evaluation of the energy metabolism in humans is lacking. Methods In 43 patients with SMA type I-III (8 type I; 22 type II; 13 type III), aged 0.6-21.8 years, auxological parameters, pubertal stage, motor function (Motor Function Measurement 32- MFM32) as well as levels of leptin, insulin glucose, hemoglobin A1c, Homeostasis Model Assessment index and an urinary steroid profile were determined. Results Hyperleptinemia was found in 15/35 (43%) of our patients; 9/15 (60%) of the hyperleptinemic patients were underweight, whereas 1/15 (7%) was obese. Hyperleptinemia was associated with SMA type (p = 0.018). There was a significant association with decreased motor function (MFM32 total score in hyperleptinemia 28.5%, in normoleptinemia 54.7% p = 0.008, OR 0.969; 95%-CI: 0.946-0.992). In addition, a higher occurrence of hirsutism, premature pub-arche and a higher variability of the urinary steroid pattern were found. Conclusion Hyperleptinemia is highly prevalent in underweight children with SMA and is associated with disease severity and decreased motor function. Neuronal degradation of hypothalamic cells or an increase in fat content by muscle remodeling could be the cause of hyperleptinemia.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] Different patterns of muscle wasting in a family with autosomal recessive childhood spinal muscular atrophy
    Vlaski-Jekic, S.
    Koceva, S.
    Kiteva, G.
    EUROPEAN JOURNAL OF NEUROLOGY, 2004, 11 : 143 - 143
  • [22] GENETICS OF INFANTILE SPINAL MUSCULAR-ATROPHY - EXISTENCE OF 2 AUTOSOMAL RECESSIVE FORMS
    FEINGOLD, J
    ARTHUIS, M
    CELERS, J
    ANNALES DE GENETIQUE, 1977, 20 (01): : 19 - 23
  • [23] Spinal muscular atrophy-type I
    Hardart, MKM
    Truog, RD
    ARCHIVES OF DISEASE IN CHILDHOOD, 2003, 88 (10) : 848 - 850
  • [24] Which care for children with spinal muscular atrophy type I and their families at hospital?
    Jouinot, Patricia
    Estournet, Brigitte
    MEDECINE PALLIATIVE, 2010, 9 (06): : 303 - 308
  • [25] Evidence for compound heterozygosity causing mild and severe forms of autosomal recessive spinal muscular atrophy
    Talbot, K
    Rodrigues, N
    Bernert, G
    Bittner, R
    Davies, K
    JOURNAL OF MEDICAL GENETICS, 1996, 33 (12) : 1019 - 1021
  • [26] Evidence for autosomal recessive inheritance in the infantile spinal muscular atrophy variant with congenital fractures.
    Courtens, W
    Johansson, A
    Dachy, B
    Avni, F
    Telerman-Toppet, N
    Scheffer, H
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2002, 10 : 254 - 255
  • [27] Developmental milestones in type I spinal muscular atrophy
    De Sanctis, Roberto
    Coratti, Giorgia
    Pasternak, Amy
    Montes, Jacqueline
    Pane, Marika
    Mazzone, Elena S.
    Young, Sally Dunaway
    Salazar, Rachel
    Quigley, Janet
    Pera, Maria C.
    Antonaci, Laura
    Lapenta, Leonardo
    Glanzman, Allan M.
    Tiziano, Danilo
    Muntoni, Francesco
    Darras, Basil T.
    De Vivo, Darryl C.
    Finkel, Richard
    Mercuri, Eugenio
    NEUROMUSCULAR DISORDERS, 2016, 26 (11) : 754 - 759
  • [28] Drug treatment for spinal muscular atrophy type I
    Wadman, Renske I.
    Bosboom, Wendy M. J.
    van der Pol, W. Ludo
    van den Berg, Leonard H.
    Wokke, John H. J.
    Iannaccone, Susan T.
    Vrancken, Alexander F. J. E.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2012, (04):
  • [29] Drug treatment for spinal muscular atrophy type I
    Bosboom, Wendy M. J.
    Vrancken, Alexander F. J. E.
    van den Berg, Leonard H.
    Wokke, John H. J.
    Iannaccone, Susan T.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2009, (01):
  • [30] Spectrum of Neuropathophysiology in Spinal Muscular Atrophy Type I
    Harding, Brian N.
    Kariya, Shingo
    Monani, Umrao R.
    Chung, Wendy K.
    Benton, Maryjane
    Yum, Sabrina W.
    Tennekoon, Gihan
    Finkel, Richard S.
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2015, 74 (01): : 15 - 24